Abstracts tagged "Biologicals"

Abstract Number: 0516 • ACR Convergence 2020
Characteristics of Giant Cell Arteritis Flares After Successful Treatment with Tocilizumab: Results from the Long-Term Extension of a Randomized Controlled Phase 3 Trial
Sebastian Unizony¹, Shalini V. Mohan², Jian Han² and John H. Stone¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: To investigate the characteristics of disease flare after successful treatment with tocilizumab (TCZ) in patients with giant cell arteritis (GCA).Methods: We performed a post…
Abstract Number: 0743 • ACR Convergence 2020
Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis
William Robinson¹, Chun Wu², Sarah Hu², Sean Connolly² and Sumanta Mukherjee², ¹Stanford University School of Medicine, Stanford, CT, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: ACPAs are sensitive, highly specific markers of RA. Current tests cannot differentiate ACPA+ RA subtypes. Fine-specificity ACPAs (FS) can distinguish between ACPA+ RA subtypes…
Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Sebastian Unizony¹, Joseph Dang², Jian Han³, Margaret Michalska² and Jennie H. Best², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, Inc., South San Francisco, ³Genentech, South San Francisco, CA
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
Abstract Number: 1427 • ACR Convergence 2020
Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach
Allyson Egan¹, Pasupathy Sivasothy², Robin Gore³, Caroline Owen³, Marcos Del Martinez Pero⁴, Rachel Jones⁴, Lisa Willcocks⁴, Rona Smith⁴, Stella Burns⁴ and David Jayne⁵, ¹Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., London, United Kingdom, ²Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., Cambridge, England, United Kingdom, ³Department of Respiratory medicine, Addenbrooke's Hospital, Cambridge, Cambridge, United Kingdom, ⁴Vasculitis and Lupus Clinic, Department of Medicine, Addenbrooke's Hospital, Cambridge., Cambridge, ⁵Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom
Background/Purpose: EGPA is a small vessel vasculitis characterized by the presence of tissue eosinophilia, necrotizing vasculitis and granulomatous inflammation1. In the randomized, placebo-controlled MIRRA trial…
Abstract Number: 1826 • ACR Convergence 2020
Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Ronald van Vollenhoven¹, Bevra Hahn², George Tsokos³, Peter Lipsky⁴, Robert Gordon⁵, Kaiyin Fei⁶, Kim Hung Lo⁷, Marc Chevrier⁸, Qing Zuraw⁹, Pamela Berry¹⁰, Chetan Karyekar¹⁰ and Shawn Rose¹¹, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²University of California Los Angeles, Encino, CA, ³Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ⁴RILITE Foundation, Charlottesville, VA, ⁵Janssen Research & Development, LLC, Chester Springs, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, Spring House, ⁸Janssen Research & Development, LLC, Collegeville, PA, ⁹Janssen Research & Development, LLC, Wayne, PA, ¹⁰Janssen Global Services, LLC, Horsham, PA, ¹¹Janssen Research & Development, LLC, Princeton Junction, NJ
Background/Purpose: Both IL-12 and IL-23 have been implicated in the pathogenesis of SLE. In a phase 2 study, treatment with the anti-IL-12/23 p40 monoclonal antibody…
Abstract Number: 0008 • ACR Convergence 2020
COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review
Akhil Sood¹, Arbi Galestanian¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…
Abstract Number: 0231 • ACR Convergence 2020
Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset
Helen Cooley¹, Tegan Smith², Peter Youssef³, Kathleen Tymms⁴, David Mathers⁵, Sabina Ciciriello⁶, Hedley Griffiths⁷, Catherine OSullivan² and Geoffrey Littlejohn⁸, ¹Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, ⁴Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁵Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁶Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ⁷Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia, ⁸Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia
Background/Purpose: In Australia the cost of biological/targeted synthetic DMARDs (b/tsDMARDs) for treatment of RA is subsidized if the patient has documented high levels of clinical/laboratory…
Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…
Abstract Number: 0555 • ACR Convergence 2020
Utilization and Adherence Among Infliximab Biosimilar Initiators in a U.S. National Commercial Insurance Database
Sujith Sarvesh¹, Joseph Alanaeme¹, Jeffrey R Curtis² and Huifeng Yun², ¹University of Alabama at Birmingham, BIrmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infliximab Biosimilar, the first biosimilar to infliximab, was approved for multiple indications in the U.S. in 2016. Since the utilization of biosimilar in the…
Abstract Number: 0798 • ACR Convergence 2020
A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92
Roy Fleischmann¹, Daniel Alvarez², Amy Bock³, Carol Cronenberger⁴, Ivana Vranic⁵, Wuyan Zhang⁶ and Rieke Alten⁷, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²Pfizer, Collegeville, PA, ³Pfizer, Cambridge, MA, ⁴Pfizer, Collegeville, ⁵Pfizer, Tadworth, United Kingdom, ⁶Pfizer, New York, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: To evaluate the long-term safety, immunogenicity (IG), and efficacy of the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF), in patients (pts) with moderate to severe active…
Abstract Number: 0830 • ACR Convergence 2020
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 0908 • ACR Convergence 2020
Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
Atul Deodhar¹, Philip Mease², Wolf-Henning Boehncke³, John Tesser⁴, Elena Schiopu⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Elizabeth Hsia⁸, Xie Xu⁹, May Shawi¹⁰, Yusang Jiang¹¹, Shihong Sheng¹¹, Prasheen Agarwal¹¹, Joseph Merola¹², Iain McInnes¹³ and Christopher Ritchlin¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Geneva University Hospitals, Geneva, Switzerland, ⁴Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁵Michigan Medicine, Ann Arbor, MI, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁹Janssen Research & Development, LLC, San Marcos, CA, ¹⁰Janssen Global Services, LLC, Toronto, ON, Canada, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ¹³Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ¹⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the IL-23p19-subunit, has shown consistent efficacy in psoriasis pts regardless of body weight/body mass index (BMI).1 GUS…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].